Marina del Rey

Researchers are conducting a non-interventional, open-label, observational study across multiple sites to collect real-world data on the use of an autologous hair follicle derived secretome topical cosmetic product. This product is studied as an addition to various medical aesthetic procedures, focusing on its application for conditions such as post-procedural erythema. The study includes adults aged 18 to 60 of any skin type who are planning to undergo these aesthetic treatments. Participants will use the Acorn Autologous Hair Follicle Secretome cosmetic product following their medical aesthetic procedures. The procedures involved include laser resurfacing of the face (ablative or non-ablative), Tixel treatment of the face, and treatments for acne and surgery scars combined with ablative or non-ablative laser or microneedling. Some hair-related treatments and procedures are closed to enrollment. The study observes real-world usage without intervening in treatment decisions. During the study, participants will be monitored for symptoms and downtime related to their procedures over a period of 1 to 7 days. Researchers will collect data on post-procedure symptoms and downtime using questionnaires to understand the product's impact as an adjunct to aesthetic procedures. The study ensures safety by excluding participants with conditions that may interfere with participation and by tracking any relevant health status changes throughout the observation period.

Researchers are evaluating whether fisetin, a natural substance found in strawberries and other foods, can improve physical function in postmenopausal women who have undergone chemotherapy for stage I to III breast cancer. Fisetin may help by removing aged cells that stop dividing but do not die, which build up after chemotherapy and may cause inflammation and damage to healthy cells. This phase II trial aims to test the effect of fisetin on physical function and other health measures in these breast cancer survivors. Participants are randomly assigned to receive either fisetin or a placebo orally on days 1, 2, and 3, with treatment repeating every two weeks for up to eight weeks unless there is disease progression or unacceptable side effects. Blood samples are collected throughout the trial to study biological effects. After treatment, participants are followed yearly for up to three years to monitor long-term outcomes. During the study, participants undergo assessments of physical function including a 6-minute walk test, grip strength, and frailty measures, as well as evaluations of fatigue, neuropathy, cognitive function, quality of life, sleep, anxiety, and depression through questionnaires. Safety and tolerability are monitored using standard criteria, and medication adherence is recorded using a pill diary. The study also explores molecular markers related to aging and inflammation to understand fisetin's biological effects.

Researchers are evaluating how fisetin, a natural compound found in strawberries, combined with exercise, may help prevent frailty in postmenopausal breast cancer survivors who have completed chemotherapy. This phase II trial focuses on physical function, fatigue, neuropathy, cognitive function, quality of life, and cancer survival outcomes. The study also assesses safety, adherence, and biological markers related to aging cells and inflammation. Participants are randomly assigned to one of four groups: fisetin with exercise, fisetin with a physical activity handout, placebo with exercise, or placebo with a handout. Fisetin or placebo is taken orally on days 1-3 every 14 days for 8 cycles. Exercise training involves 30-45 minutes of aerobic and 20-30 minutes of resistance exercises three times a week for 16 weeks. Blood samples are collected during the study. Throughout the study, participants undergo physical performance tests, questionnaires, and quality-of-life assessments. Wearable devices track heart rate and step count. Follow-up visits occur on days 120 and 180 after treatment, then annually for up to 3 years. The main outcome measured is change in the 6-minute walk distance from baseline to day 120, alongside other physical and health-related outcomes.

Researchers are evaluating whether combining the investigational drug mevrometostat (PF-06821497) with enzalutamide works better than enzalutamide alone in men with metastatic castration-sensitive prostate cancer (mCSPC) who have not previously received androgen receptor pathway inhibitors or chemotherapy in this setting. This Phase 3, randomized, double-blind, placebo-controlled study involves participants who have only received limited prior androgen-deprivation therapy and no evidence of disease progression before starting the study. Participants will be randomly assigned to one of two groups: one group receives oral mevrometostat together with oral enzalutamide continuously, while the other group receives a placebo with oral enzalutamide continuously. The study includes a Screening Phase, a Treatment Phase after randomization, followed by Safety Follow-up and Long-Term Follow-up periods to monitor outcomes and side effects. Throughout the study, participants will undergo regular assessments including imaging scans to evaluate disease progression, laboratory tests, and monitoring of symptoms and adverse events. The main outcome measured is Radiographic Progression Free Survival (rPFS) over approximately 4 years from randomization. Safety and long-term effects will also be monitored to understand how well participants tolerate the treatments and how the disease responds over time.